SUPN FY 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$393M-3.9% YoY

Gross Profit

$376M95.8% margin

Operating Income

$149M37.8% margin

Net Income

$113M28.8% margin

EPS (Diluted)

$2.10

Cash Flow

Operating Cash Flow

$143M

Free Cash Flow

$140M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$565M

Stockholders' Equity

$595M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$393M	$409M	-3.9%
Gross Profit	$376M	$394M	-4.4%
Operating Income	$149M	$144M	+2.9%
Net Income	$113M	$111M	+1.9%